Table 1.
Clinical features and immunohistological staining characteristics for 26 reported cases of primary ductal adenocarcinoma
| Literature | Age | Sex | Symptoms | Site | Maximum diameter (cm) | Immunostain (+) | Immunostain (−) |
|---|---|---|---|---|---|---|---|
| Our case 1 | 64 | Male | Orbital mass and proptosis for 3 months | Left | 3.9 | AR, CK7, GCDFP-15 | CK20, TTF-1, PSA, S-100 |
| Our case 2 | 64 | Male | Proptosis and diplopia for 3 weeks | Right | 5 | AR, CK7, EGFR | CK20, TTF-1 |
| Andreasen et al. 2017[9] | 77 | Male | Diplopia for 2 weeks | Left | 3.2 | AR, CK7, CK17, CK19, Cyclin D1, EGFR, EMA, GCDFP-15, Her-2, p53, Ki-67 | CEA, CK5/6, DOG1, ER, PR, PSA, S-100, α-SMA |
| 53 | Male | Proptosis of the left eye for 5 years | Left | 2 | CK5, CK6, CK7, CK19, Cyclin D1, EGFR, EMA, Her-2, p53, AR, CEA, CK17, GCDFP-15, Ki67 | DOG1, ER, PR, PSA, S-100, α-SMA | |
| 73 | Male | Proptosis for 5 years | Right | 4 | CK7, CK19, EGFR, EMA, Her-2, p53, CEA, CK17, Cyclin D1, GCDFP-15, Ki-67 | AR, CK5/6, DOG1, ER, PR, PSA, S-100, α-SMA | |
| Dennie, 2015[7] | 53 | Female | Headache, blurred vision, and proptosis | Right | 3 | Keratin, CK7, mammaglobin | CK20, TTF-1, GCDFP-15, ER, PR |
| Lau et al. 2015[8] | 34 | Female | Right upper eyelid swelling for 1 year | Right | 2.8 | EMA, CD117, PAS | S-100, CK20, Melan A |
| Zhu et al. 2015[3] | 49 | Female | Painless, palpable mass, double vision, and epiphora for 6 months | Left | 1.1 | GCDFP-15, AR, Her-2, p53, Ki-67, CK18 | ER, PR, P63, calponin, CD117 |
| Ricci et al. 2014[5] | 71 | Male | Lumbar pain for 3 years and slight exophthalmos for several years | Right | 2.3 | AR, GCDFP-15, CK7, Her-2 | TTF-1, PSA, ER, PR, CK20, CDX2 |
| Min et al. 2014[6] | 46 | Male | Exophthalmos and blurred vision for 2 months | Left | 3 | CK5, CK7, CK20 | S-100, TTF-1, PSA |
| Kubota et al. 2013[11] | 75 | Male | Upper eyelid swelling for 3 months | Right | 2.8 | AR, Her-2, p53, Ki-67 | ER, PR |
| 67 | Male | Upper eyelid swelling and ptosis for 6 months | Left | 4 | AR, p53, Ki-67 | Her-2, ER, PR | |
| 53 | Male | Upper eyelid swelling and ptosis for 18 months | Right | 3.7 | AR, p53, Ki-67 | Her-2, ER, PR | |
| 39 | Male | Upper eyelid swelling for 6 months | Left | 2.5 | AR, Her-2, p53, Ki-67 | ER, PR | |
| 46 | Female | Upper eyelid swelling for 1 months | Right | 2.5 | AR, Her-2, p53, Ki-67 | ER, PR | |
| Damasceno and Holbach, 2012[12] | 78 | Male | Diplopia, painless, palpable mass, and restricted abduction | Right | 2.4 | CK7, MMP2, MMP9, MMP13, Her-2 | CK5, CK20, p63, PSA, S100, TTF1 |
| Giliberti et al. 2011[10] | 17 | Male | Right orbital mass for 6 months | Right | NA | NA | NA |
| Ishida et al. 2009[13] | 70 | Female | Painful exophthalmos | Left | 2.5 | GCDFP15, Ki-67 | AR, Her-2, ER, PR |
| Lee and Oh, 2009[14] | 50 | Male | Exophthalmos | Right | 4 | CK7, CK19, EMA | Her-2, ER, PR, CK20, p53, S-100, α-SMA |
| Kim et al. 2008[15] | 47 | Male | Left lacrimal gland mass | Left | NA | NA | NA |
| Takahira et al. 2007[4] | 48 | Female | Progressive exophthalmos for 3 years | Left | 3.8 | AR, GCDFP-15 | ER, PR |
| Milman et al. 2005[16] | 59 | Male | Orbital mass and blepharoptosis 15 years | Right | 1.5 | GCDFP-15, keratin AE1, CK7, CEA, EMA, CK20 | TTF-1, PSA, Her-2, ER, p53, S-100 |
| Kurisu et al. 2005[17] | 67 | Male | Visual disturbance | Right | 3 | CK7, CK10, CK17, CK18, CK19 | S-100, α-SMA, CK20 |
| Krishnakumar et al. 2003[18] | 46 | Male | Firm irregular mass with progressive ptosis in the orbit 2 years | Left | NA | NA | NA |
| Paulino and Huvos, 1999[19] | 52 | Female | NA | Right | NA | NA | NA |
| Nasu et al. 1998[20] | 67 | Male | Small nodule in the upper eyelid | Right | 2.5 | EMA, CK, CEA, S-100 | Actin, ER, PSA |
| Katz et al. 1996[2] | 68 | Male | Lump in the upper outer eyelid | Right | 4 | Keratin | HMB-45, NSE, S-100, chromogranin, CEA, PSA |
AR=Androgen receptor, CDX2=Caudal-type homeobox 2, CEA=Carcinoembryonic antigen, CK=Cytokeratin, EGFR=Epidermal growth factor receptor, EMA=Epithelial membrane antigen, ER=Estrogen receptor, GCDFP-15=Gross cystic disease fluid protein 15, Her-2=Human epidermal growth factor receptor 2, MMPs=Matrix metalloproteinases, NA=Not available, NSE=Neuronspecific enolase, PAS=Periodic acid–Schiff, PR=Progesterone receptor, PSA=Prostate-specific antigen, SMA=Smooth muscle actin, TTF-1=Thyroid transcription factor-1